Predictors of steroid non-response and new approaches in severe alcoholic hepatitis

키워드

참고문헌 (67)

1. Shasthry SM, "New treatment options for alcoholic hepatitis", World J Gastroenterol, 22, pp.3892~3906 (2016)
2. André T, "Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy(OPTIMOX2)with celecoxib in metastatic colorectal cancer : a GERCOR study", Ann Oncol, 18, pp.77~81 (2007)
3. Maras JS, "Baseline urine metabolic phenotype in patients with severe alcoholic hepatitis and its association with outcome", Hepatol Commun, 2, pp.628~643 (2018)
4. Gao B, "Alcoholic liver disease : pathogenesis and new therapeutic targets", Gastroenterology, 141, pp.1572~1585 (2011)
5. Crabb DW, "Standard definitions and common data elements for clinical trials in patients with alcoholic hepatitis : recommendation from the NIAAA alcoholic hepatitis consortia", Gastroenterology, 150, pp.785~790 (2016)
6. Shasthry SM, "Efficacy of granulocyte colony-stimulating factor in the management of steroidnonresponsive severe alcoholic hepatitis : a double-blind randomized controlled trial", Hepatology, 70, pp.802~811 (2019)
7. Thursz MR, "Prednisolone or pentoxifylline for alcoholic hepatitis", N Engl J Med, 372, pp.1619~1628 (2015)
8. Kedarisetty CK, "Insights into the role of granulocyte colony stimulating factor in severe alcoholic hepatitis", Semin Liver Dis (2020)
9. Maddrey WC, "Corticosteroid therapy of alcoholic hepatitis", Gastroenterology, 75, pp.193~199 (1978)
10. Duseja A, "APACHE II score is superior to SOFA, CTP and MELD in predicting the shortterm mortality in patients with acute-on-chronic liver failure(ACLF)", J Dig Dis, 14, pp.484~490 (2013)
11. Thursz M, "Treatment of severe alcoholic hepatitis", Gastroenterology, 150, pp.1823~1834 (2016)
12. Louvet A, "The Lille model : a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids", Hepatology, 45, pp.1348~1354 (2007)
13. Mathurin P, "Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis : meta-analysis of individual patient data", Gut, 60, pp.255~260 (2011)
14. Mathurin P, "Early liver transplantation for severe alcoholic hepatitis", N Engl J Med, 365, pp.1790~1800 (2011)
15. Dao A, "Steroids for severe alcoholic hepatitis : more risk than reward?", Clin Liv Dis, 12, pp.151~153 (2018)
16. Louvet A, "Infection in patients with severe alcoholic hepatitis treated with steroids : early response to therapy is the key factor", Gastroenterology, 137, pp.541~548 (2009)
17. Garcia-Saenz-de-Sicilia M, "A day-4 Lille model predicts response to corticosteroids and mortality in severe alcoholic hepatitis", Am J Gastroenterol, 112, pp.306~315 (2017)
18. Shasthry SM, "Histological activity score on baseline liver biopsy can predict non-response to steroids in patients with severe alcoholic hepatitis", Virchows Arch, 472, pp.667~675 (2018)
19. Sukriti S, "Microvesicles in hepatic and peripheral vein can predict nonresponse to corticosteroid therapy in severe alcoholic hepatitis", Ailment Pharmacol Ther, 47, pp.1151~1161 (2018)
20. Sharma S, "Pre-therapy liver transcriptome landscape in Indian and French patients with severe alcoholic hepatitis and steroid responsiveness", Sci Rep, 7, pp.6816~ (2017)
21. Petta I, "The interactome of the glucocorticoid receptor and its influence on the actions of glucocorticoids in combatting inflammatory and infectious diseases", Microbiol Mol Biol Rev, 80, pp.495~522 (2016)
22. Das S, "Hyperoxidized albumin modulates neutrophils to induce oxidative stress and inflammation in severe alcoholic hepatitis", Hepatology, 65, pp.631~646 (2017)
23. Tay J, "Cellular players of hematopoietic stem cell mobilization in the bone marrow niche", Int J Hematol, 105, pp.129~140 (2017)
24. Scadden D, "Hematology", pp.119~126 (2018), Elsevier
25. Karakike E, "Infections in severe alcoholic hepatitis", Ann Gastroenterol, 30, pp.152~160 (2017)
26. Mookerjee RP, "Neutrophil dysfunction in alcoholic hepatitis superimposed on cirrhosis is reversible and predicts the outcome", Hepatology, 46, pp.831~840 (2007)
27. Artru F, "IL-33", ST2 pathway regulates neutrophil migration and predicts outcome in patients with severe alcoholic hepatitis, 2020, pp.72, 1052~1061
28. Sarin SK, "Acute-on-chronic liver failure : consensus recommendations of the Asian Pacific association for the study of the liver(APASL) : an update", Hepatol Int, 13, pp.353~390 (2019)
29. Khanam A, "Altered frequencies of dendritic cells and IFN-γ-secreting T cells with granulocyte colony-stimulating factor(G-CSF)therapy in acuteon-chronic liver failure", Liver Int, 34, pp.505~513 (2014)
30. Katayama Y, "Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow", Cell, 124, pp.407~421 (2006)
31. Piscaglia AC, "Granulocyte-colony stimulating factor promotes liver repair and induces oval cell migration and proliferation in rats", Gastroenterology, 133, pp.619~631 (2007)
32. Garg V, "Granulocyte colony-stimulating factor mobilizes CD34+ cells and improves survival of patients with acute-on-chronic liver failure", Gastroenterology, 142, pp.505~512.e1 (2012)
33. Singh V, "Granulocyte colony-stimulating factor in severe alcoholic hepatitis : a randomized pilot study", Am J Gastroenterol, 109, pp.1417~1423 (2014)
34. Prajapati R, "Granulocyte colony-stimulating factor improves survival of patients with decompensated cirrhosis : a randomized-controlled trial", Eur J Gastroenterol Hepatol, 29, pp.448~455 (2017)
35. Marot A, "Granulocyte colony-stimulating factor for alcoholic hepatitis : a systematic review and metaanalysis of randomised controlled trials", JHEP Rep, 2, pp.100139~ (2020)
36. Gameiro J, "Acute kidney injury definition and diagnosis : a narrative review", J Clin Med, 7, pp.307~ (2018)
37. Bihari C, "Bone marrow stem cells and their niche components are adversely affected in advanced cirrhosis of the liver", Hepatology, 64, pp.1273~1288 (2016)
38. Anand L, "Early cirrhosis and a preserved bone marrow niche favour regenerative response to growth factors in decompensated cirrhosis", Liver Int, 39, pp.115~126 (2019)
39. Liu Y, "Probiotic Lactobacillus rhamnosus GG prevents liver fibrosis through inhibiting hepatic bile acid synthesis and enhancing bile acid excretion in mice", Hepatology, 71, pp.2050~2066 (2020)
40. Sarin SK, "Microbiome as a therapeutic target in alcohol-related liver disease", J Hepatol, 70, pp.260~272 (2019)
41. Kamada N, "Control of pathogens and pathobionts by the gut microbiota", Nat Immunol, 14, pp.685~690 (2013)
42. Llopis M, "Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease", Gut, 65, pp.830~839 (2016)
43. Xie G, "Chronic ethanol consumption alters mammalian gastrointestinal content metabolites", J Proteome Res, 12, pp.3297~3306 (2013)
44. Chen P, "Supplementation of saturated long-chain fatty acids maintains intestinal eubiosis and reduces ethanol-induced liver injury in mice", Gastroenterology, 148, pp.203~214.e16 (2015)
45. Inagaki T, "Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor", Proc Natl Acad Sci U S A, 103, pp.3920~3925 (2006)
46. Hartmann P, "Modulation of the intestinal bile acid", farnesoid X receptor, Hepatology, pp.2018, 67[DOI]
47. Philips CA, "Healthy donor fecal microbiota transplantation in steroidineligible severe alcoholic hepatitis : a pilot study", Clin Gastroenterol Hepatol, 15, pp.600~602 (2017)
48. Bajaj JS, "Long-term outcomes after fecal microbiota transplantation in cirrhosis", Gastroenterology, 156, pp.1921~1923 (2019)
49. Kelly CR, "Update on fecal microbiota transplantation 2015 : indications, methodologies, mechanisms, and outlook", Gastroenterology, 149, pp.223~237 (2015)
50. Defilipp Z, "Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant", N Engl J Med, 381, pp.2043~2050 (2019)
51. Szabo G, "IL-1 Receptor antagonist in combination with pentoxifylline and zinc for severe alcoholic hepatitis : a multicenter randomized double-bind placebo-controlled clinical trial", Hepatology, 68, pp.1444A~1471A (2018)
52. Zirnheld KH, "Dietary fatty acids and bioactive fatty acid metabolites in alcoholic liver disease", Liv Res, 3, pp.206~217 (2019)
53. "Oral abstracts (abstracts 1–263)", Hepatology, 66, pp.1~148 (2017)
54. Anand L, "Short-term infusion of soyabean oil based intravenous lipid emulsion is safe in patients with acute-on-chronic liver failure(ACLF), improves nitrogen balance and preserves immune functions : 2088", Hepatology, 62, pp.197A~ (2015)
55. Kalal C, "Effect of long term aggressive nutritional therapy on survival in patients with alcoholic liver cirrhosis-interim analysis of a randomized controlled trial", Hepatology, 64(Suppl 1), pp.705A~706A (2016)
56. Maiwall R, "Liver dialysis in acute-onchronic liver failure: current and future perspectives", Hepatol Int, 8(Suppl 2), pp.505~513 (2014)
57. Bañares R, "Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure : the RELIEF trial", Hepatology, 57, pp.1153~1162 (2013)
58. Kribben A, "Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure", Gastroenterology, 142, pp.782~789.e3 (2012)
59. Maiwall R, "Therapeutic plasma-exchange improves systemic inflammation and survival in patients with acute on chronic liver failure", J Hepatol, 68, pp.S45~ (2018)
60. Phillips M, "Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis--a randomised clinical trial", J Hepatol, 44, pp.784~790 (2006)
61. Nguyen-Khac E, "Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis", N Engl J Med, 365, pp.1781~1789 (2011)
62. Rambaldi A, "S-adenosyl-L-methionine for alcoholic liver diseases", Cochrane Database Syst Rev, (2), pp.CD002235~ (2006)
63. Morris JM, "Granulocytapheresis in the treatment of severe alcoholic hepatitis : a case series", Eur J Gastroenterol Hepatol, 22, pp.457~460 (2010)
64. Kamimura K, "Granulocytapheresis for the treatment of severe alcoholic hepatitis : a case series and literature review", Dig Dis Sci, 59, pp.482~488 (2014)
65. Schulert GS, "Pathogenesis of macrophage activation syndrome and potential for cytokine-directed therapies", Annu Rev Med, 66, pp.145~159 (2015)
66. Shakoory B, "Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome : reanalysis of a prior phase III trial", Crit Care Med, 44, pp.275~281 (2016)
67. Sarin SK, "Acute-on-chronic liver failure : terminology, mechanisms and management", Nat Rev Gastroenterol Hepatol, 13, pp.131~149 (2016)

관련 논문AI추천